The safety and feasibility of large volume paracentesis performed by an experienced nurse practitioner
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 4
Abstract
Due to time constraints, fewer physicians are performing large volume paracentesis (LVP) resulting in a longer wait time and more emergency department (ED) and hospital admissions. At our institution, after initial supervision, a certified nurse practitioner (NP) has independently performed LVP in a dedicated cirrhosis clinic. The purpose of our study was to evaluate the feasibility and safety of LVP performed by a NP. A retrospective review of patients undergoing LVP between January 2003 and May 2007 was performed. Baseline patient information and the practitioner performing LVP (physician or NP) were recorded. Complications including post paracentesis hypotension, bleeding, local leakage of ascitic fluid, infection, perforation, and death were compared between the two groups. A total of 245 procedures in 41 patients were performed by a single NP, and 244 in 43 patients by physicians. Baseline characteristics of patients undergoing LVP were similar in two groups. Alcohol was the most common etiology of cirrhosis (46% in NP and 51% in physician group) followed by a combination of alcohol plus HCV (37% in NP and 28% in physician group). There was similar distribution of Childs class B and C patients in the two groups, as well as average MELD score. Total volume of ascites removed, number of needle attempts, and complications including post paracentesis hypotension, local leakage of ascitic fluid, bleeding, infection, and death were not statistically different between the two groups. Our study shows no difference between physician and NP performance of LVP and complication rates. LVP performed by a NP is feasible and has acceptable rate of complications.
Authors and Affiliations
Nooman Gilani, Nayan Patel, Richard Gerkin, Francisco Ramirez, Erin Tharalson, Kandarp Patel
Keywords
Related Articles
- EP ID EP77892
- DOI -
- Views 125
- Downloads 0
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
Purpose. Chronic hepatitis C virus (HCV) is a major problem affecting up to 170 million people worldwide. Two protease inhibitors have recently been approved that will revolutionize treatment. Our objective was to summar...
Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B
Background. Long-term lamivudine (LAM), adefovir (ADV) and entecavir (ETV) treatment induce the emergence of drug-resistant hepatitis B virus (HBV) in patients with chronic hepatitis B infection. Aim. To evaluate the LAM...
Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1
Introduction. Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension. This uncontrolled interventional pilot study examines the hemodynamic and...
It TAK(es) 1 to prevent steatohepatitis and tumorigenesis
The effect of ursodeoxycholic acid in cystic cholangiopathies